HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Circulating Neoplastic Cells

Subscribe to New Research on Circulating Neoplastic Cells

Exfoliate neoplastic cells circulating in the blood and associated with metastasizing tumors.

Also Known As:

Neoplastic Cells, Circulating; Cells, Neoplasm Circulating; Circulating Cells, Neoplasm; Circulating Tumor Cells; Cell, Circulating Neoplastic; Cell, Circulating Tumor; Cell, Embolic Tumor; Cell, Neoplasm Circulating; Cells, Circulating Neoplastic; Cells, Circulating Tumor; Cells, Embolic Tumor; Circulating Neoplastic Cell; Circulating Tumor Cell; Embolic Tumor Cell; Embolisms, Tumor; Neoplasm Circulating Cell; Neoplastic Cell, Circulating; Tumor Cell, Circulating; Tumor Cell, Embolic; Tumor Cells, Circulating; Tumor Embolism; Tumor Embolisms; Embolic Tumor Cells; Embolism, Tumor; Neoplasm Circulating Cells; Tumor Cells, Embolic

Networked: 1072 relevant articles (30 outcomes, 121 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Breast Neoplasms (Breast Cancer)
3.	Carcinoma (Carcinomatosis)
4.	Prostatic Neoplasms (Prostate Cancer)
5.	Neoplasm Metastasis (Metastasis)

Experts

1.	Pantel, Klaus: 28 articles (07/2015 - 06/2004)
2.	Georgoulias, Vassilis: 16 articles (01/2015 - 01/2006)
3.	Mavroudis, Dimitris: 15 articles (01/2015 - 01/2006)
4.	Scher, Howard I: 14 articles (06/2015 - 04/2007)
5.	Riethdorf, Sabine: 12 articles (07/2015 - 05/2005)
6.	Gradilone, Angela: 11 articles (10/2015 - 01/2003)
7.	Alix-Panabières, Catherine: 10 articles (03/2015 - 11/2007)
8.	King, Michael R: 9 articles (12/2015 - 01/2012)
9.	Ignatiadis, Michail: 9 articles (11/2015 - 09/2006)
10.	de Bono, Johann S: 9 articles (10/2015 - 06/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Circulating Neoplastic Cells:

1.	Biological Markers (Surrogate Marker)IBA 08/01/2009 - "Serological cell death biomarkers and circulating tumor cells (CTCs) have potential uses as tools for pharmacodynamic blood-based assays and their subsequent application to early clinical trials. " 02/01/2009 - "Blood-based biomarkers may identify patients in whom a specific therapy provides clinical benefit, and this study sought to characterize circulating tumor cells (CTCs) in patients with metastatic UC. " 12/01/2015 - "Unlike circulating tumor cells they are highly abundant in biofluids and, on the contrary to single-molecule circulating biomarkers, they protect their molecular cargo against degradation and may carry molecular signatures associated with specific phenotypes. " 06/20/2015 - "Circulating tumor cells (CTCs) are considered as surrogate markers for prognosticating and evaluating patient treatment responses. " 05/10/2015 - "Secondary end points included the proportion of patients with PSA > 4.0 ng/mL, safety and tolerability, circulating tumor cell (CTC) levels, and seven plasma IGF-IR biomarkers. "
2.	Messenger RNA (mRNA)IBA 06/01/2006 - "In future, measurement of Tg mRNA to detect circulating tumor cells may help to overcome some of the current limitations. " 01/01/2014 - "The aim of this study was to investigate whether the detection of LUNX mRNA-positive circulating tumor cells (CTC)s in peripheral blood at different time points is useful for predicting disease recurrence, disease-free survival (DFS), and overall survival (OS) in NSCLC patients undergoing surgery. " 06/16/2015 - "Sample-to-Answer Isolation and mRNA Profiling of Circulating Tumor Cells." 02/15/2013 - "AGR2 mRNA levels were measured with RT-PCR in circulating tumor cell (CTC)-enriched peripheral blood. " 04/24/2012 - "And CK19 mRNA was measured by quantitative reverse transcription-polymerase chain reaction in blood as an index of circulating tumor cells in the patients. "
3.	lapatinib (GW572016)FDA Link 11/01/2010 - "Although a proof for the clinical significance of EGFR-positive circulating tumor cells is currently lacking, expression of EGFR may predict response to lapatinib-based treatments as in the case presented." 01/01/2015 - "Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer." 11/01/2013 - "Following the identification of HER2-activating events in the most recent lung carcinoma and in circulating tumor cells, we treated the reminiscent metastatic lesions with a lapatinib-based therapy. " 07/01/2012 - "Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. " 01/01/2013 - "The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study."
4.	tumor-associated antigen GA733IBA 10/01/2015 - "Circulating tumor cells isolation: the "post-EpCAM era"." 09/29/2015 - "Conventional strategy of anti-EpCAM capture and immunostaining of cytokeratins (CKs) to detect circulating tumor cells (CTCs) is limited by highly heterogeneous and dynamic expression or absence of EpCAM and/or CKs in CTCs. " 01/01/2015 - "It has been considered that the detection methods for circulating tumor cells (CTCs) based on epithelial cell adhesion molecule (EpCAM) underestimate the number of CTCs and may miss a metastatic subpopulation with cancer stem cell (CSC) properties. " 01/01/2015 - "The detection of EpCAM(+) and EpCAM(-) circulating tumor cells." 08/01/2014 - "Identification of novel markers that outperform EpCAM in quantifying circulating tumor cells."
5.	AntigensIBA 11/01/2010 - "Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies." 12/01/2014 - "Most circulating tumor cell (CTC) detection methods have technical limitations, allowing the detection of only cells expressing epithelial antigens, and they cannot identify if the CTCs are alive or dead. " 02/01/2011 - "Novel methods, including the detection of circulating tumor cells and carcinoembryonic antigens in serum, have been developed, and their prognostic and predictive characteristics have been assessed. " 10/01/2010 - "Assessing the presence of target antigens on circulating tumor cells (CTCs) might affect treatment choice. " 02/01/2009 - "Current immunomagnetic enrichment method can only detect general epithelial antigens of circulating tumor cells (CTC). "
6.	Epidermal Growth Factor Receptor (EGF Receptor)IBA 01/01/2015 - "Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients." 01/01/2013 - "Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer." 04/01/2000 - "Detection of circulating tumor cells in carcinoma patients by a novel epidermal growth factor receptor reverse transcription-PCR assay." 10/20/2005 - "Modulation of epidermal growth factor receptor-positive circulating tumor cells by chemotherapy in non-small-cell lung cancer patients." 03/01/2001 - "Detection of epidermal growth factor receptor mRNA in peripheral blood: a new marker of circulating neoplastic cells in bladder cancer patients."
7.	FibrinIBA 01/01/1979 - "Blood fibrin being deposited around the circulating tumor cells seems to contribute to metastatic spread, thus enhancing the cell implantation. " 10/10/2009 - "TF on circulating tumor cells also leads to the coating of the cells with fibrin that traps them within the microvasculature and facilitates hematogenous metastasis. " 06/01/1978 - "The presumed mechanism of increased survival is an inhibition of fibrin deposition around circulating tumor cells, thereby preventing their adherence to capillary endothelium to initiate metastasis formation." 01/01/1996 - "Fibrin deposits surrounding circulating tumor cells may protect them from mechanical trauma and destruction by the host immune system, and may facilitate microvascular entrapment required for metastasis. " 10/01/1999 - "DDAVP may help to dissolve the protective fibrin shield of circulating tumor cells. "
8.	gemcitabine FDA Link 08/01/2014 - "Gemcitabine inhibits the micrometastasis of non-small cell lung cancer by targeting the EpCAM-positive circulating tumor cells via the HGF/cMET pathway." 07/01/2014 - "To evaluate the association in the change of circulating tumor cell (CTC) levels and clinical outcomes (PFS and OS) in patients with advanced non-small cell lung cancer (NSCLC) treated homogenously with docetaxel and gemcitabine administered every 2 weeks. " 07/01/2014 - "Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine." 07/01/2011 - "In the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, researchers have presented several interesting results in biomarkers development: the identifications of 9 single nucleotide polymorphisms (SNPs) that is associated with positive efficacy of gemcitabine (Abstract #4022); the introduction of circulating tumor cells as a prognostic markers in pancreatic adenocarcinoma (Abstract #e14657); the re-affirmation of plasma cytidine deaminase (CDA) as a positive predictive markers for gemcitabine efficacy, as well as the postulations that CDA*3 as a potential genotype marker to predict gemcitabine responses (Abstract #e14645); and finally the retrospective tumor tissues analysis in the Arbeitsgemeinschaft Internistische Onkologie (AIO) trial in an attempt for epidermal growth factor receptor (EGFR) pathway biomarker identifications (Abstract #4047)."
9.	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/01/2015 - "In this preliminary effort, we report an approach to eliminate circulating tumor cells from the blood stream by flowing the blood though an extracorporeal tube and applying photodynamic therapy (PDT). " 11/01/2013 - "The results demonstrate the efficacy of systemic PDT for elimination of tumor cells circulating in the peripheral blood of cancer patients with different localization of primary tumor and stage of disease." 11/01/2013 - "The aim of this investigation is to study the number of circulating tumor cells (CTCs) in the blood of cancer patients after systemic photodynamic therapy (PDT) at different times and to assess apoptosis of these cells. "
10.	Cytidine DeaminaseIBA 07/01/2011 - "In the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, researchers have presented several interesting results in biomarkers development: the identifications of 9 single nucleotide polymorphisms (SNPs) that is associated with positive efficacy of gemcitabine (Abstract #4022); the introduction of circulating tumor cells as a prognostic markers in pancreatic adenocarcinoma (Abstract #e14657); the re-affirmation of plasma cytidine deaminase (CDA) as a positive predictive markers for gemcitabine efficacy, as well as the postulations that CDA*3 as a potential genotype marker to predict gemcitabine responses (Abstract #e14645); and finally the retrospective tumor tissues analysis in the Arbeitsgemeinschaft Internistische Onkologie (AIO) trial in an attempt for epidermal growth factor receptor (EGFR) pathway biomarker identifications (Abstract #4047)."

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 11/01/2012 - "This study investigated the prognostic value of circulating tumor cells (CTCs) in patients with SCLC and whether changes in CTCs can predict response to chemotherapy. " 07/01/1982 - "This study may have bearing on the design of adjuvant intraoperative and perioperative chemotherapy in order to destroy circulating tumor cells." 07/01/1968 - "[Circulating tumor cells and cytostatic chemotherapy in the light of current experimental studies]." 10/01/2014 - "Blood samples for circulating tumor cell analysis were obtained before the initiation of chemotherapy and after the first and fourth cycle of chemotherapy. " 01/01/2012 - "Assessment of γ-H2AX levels in circulating tumor cells from patients receiving chemotherapy."
2.	Castration 02/15/2009 - "Quantitative analysis of circulating tumor cells as a survival predictor in metastatic castration-resistant prostate cancer: missing parts in a superb study." 01/01/2016 - "Men with metastatic castration-resistant prostate cancer (mCRPC) frequently have circulating tumor cells (CTCs) that are detectable in their peripheral blood. " 12/08/2015 - "Although circulating tumor cell (CTC) enumeration in peripheral blood has already been validated as a reliable biomarker in predicting prognosis in metastatic castration-resistant prostate cancer (mCRPC), patients with favorable CTC counts (CTC < 5/7.5 ml) still experience various survival times. " 12/01/2015 - "A Stepping Stone Toward Personalized Oncology: Genomic Analysis of Circulating Tumor Cells to Guide Management of Metastatic Castration-resistant Prostate Cancer." 10/01/2015 - "Circulating tumor cells (CTCs) have known prognostic implications in metastatic castration-resistant prostate cancer, but little is known regarding its utility in biochemical recurrence (BR) of prostate cancer. "
3.	Radiotherapy 08/01/2014 - "To review the results from previous studies aiming at the molecular characterization of circulating tumor cells (CTC), to specifically address the role of epithelial-mesenchymal-transition (EMT) and stemness features of CTC in their contribution to tumor progression and to summarize potential interference of CTC with the efficacy of radiotherapy. " 01/01/2014 - "The aim of this study was to evaluate the prognostic value of circulating tumor cells (CTC) in nonmetastatic rectal cancer patients treated with short-term preoperative radiotherapy. " 01/01/2014 - "Evaluation of prognostic significance of circulating tumor cells detection in rectal cancer patients treated with preoperative radiotherapy: prospectively collected material data." 10/01/2005 - "Fluctuation of circulating tumor cells in patients with lung cancer by real-time fluorescent quantitative-PCR approach before and after radiotherapy." 09/25/1989 - "Thus, radiotherapy for HCC is effective not only for the primary tumor but for tumor embolism as well, and this is a particularly useful modality for the latter."
4.	Heterologous Transplantation (Xenotransplantation) 01/01/2013 - "Furthermore, we demonstrate for the first time that VACV was effective in preventing and reducing circulating tumor cells in mice bearing human tumor xenografts. " 06/01/2015 - "Circulating tumor cells containing ER mutations can be cultured ex vivo, and tumor tissues can be grown as patient-derived xenografts to add a new dimension for testing drug susceptibility for future drug discovery. " 01/01/2015 - "A correction was made to Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells. " 01/01/2015 - "Erratum: Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells." 01/01/2015 - "Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells."
5.	Therapeutics 01/01/2013 - "The measurement and characterization of circulating tumor cells (CTCs) hold promise for advancing personalized therapeutics. " 10/22/2013 - "Sensitive and quantitative assessment of changes in circulating tumor cells (CTCs) can help in cancer prognosis and in the evaluation of therapeutics efficacy. " 01/01/2013 - "Analysis of circulating tumor cells (CTCs) provides real-time measures of cancer sub-populations with potential for CTC-directed therapeutics. " 12/01/2015 - "However, without the understanding of the biology as well as preferential homing ability of circulating tumor cells at distant organs, it is quite impossible to address the existing challenges in the present diagnostics and therapeutics against the breast cancer metastasis. " 04/01/2014 - "miRNAs are readily detected in body fluids, for example, serum, plasma, urine, as well as circulating tumor cells to demonstrate their potential as readily accessible, non-invasive diagnostic and prognostic biomarkers and potential therapeutics. "